Wednesday, July 8, 2026

Patent intelligence · US

US 8652776

Prediction of QT prolongation based on SNP genotype

granted A61PA61P25/18A61P25/20A61P25/24
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 8
Applicant portfolio 96
Patent details — US 8652776
Jurisdiction
US
Status
granted
Grant date
Feb 18, 2014
Expiration
Feb 13, 2034
Claims
8
CPC classes
A61P, A61P25/18, A61P25/20, A61P25/24
View on Google Patents ↗

Quick answer

US 8652776 (Prediction of QT prolongation based on SNP genotype) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Feb 18, 2014. Expires Feb 13, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61P, A61P25/18, A61P25/20, A61P25/24, A61P9/06

More from VANDA PHARMACEUTICALS INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12427132

    Method of improving sleep

    VANDA PHARMACEUTICALS INC. · Expires Sep 25, 2045

    granted
  2. US 12419869

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. · Expires Sep 18, 2045

    granted
  3. US 12409167

    Pharmaceutical combination comprising a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Expires Sep 4, 2045

    granted
  4. US 12403134

    Method for improving or enhancing cognition

    VANDA PHARMACEUTICALS INC. · Expires Aug 28, 2045

    granted
  5. US 12357616

    Methods of treating multiple sclerosis

    VANDA PHARMACEUTICALS INC. · Expires Jul 10, 2045

    granted
  6. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Expires Jun 19, 2045

    granted
  7. US 12318375

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Expires May 29, 2045

    granted
  8. US 12201604

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Expires Jan 16, 2045

    granted

Frequently asked questions

What is US patent 8652776?

US 8652776 (Prediction of QT prolongation based on SNP genotype) is held by VANDA PHARMACEUTICALS INC.. Status: granted. Granted Feb 18, 2014. Expires Feb 13, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8652776?

VANDA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 96 pharmaceutical patents for this assignee.

When does US 8652776 expire?

Our index shows an expiration date of Feb 13, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.